Phase 1 × Carcinoma, Non-Small-Cell Lung × fludarabine × Clear all
NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
16 enrolled